Literature DB >> 26433377

Dopamine Burden Triggers Neurodegeneration via Production and Release of TNF-α from Astrocytes in Minimal Hepatic Encephalopathy.

Saidan Ding1, Weikan Wang2, Xuebao Wang1, Yong Liang1, Leping Liu3, Yiru Ye4, Jianjing Yang2, Hongchang Gao5, Qichuan Zhuge6.   

Abstract

Dopamine (DA)-induced learning and memory impairment is well documented in minimal hepatic encephalopathy (MHE), but the contribution of DA to neurodegeneration and the involved underlying mechanisms are not fully understood. In this study, the effect of DA on neuronal apoptosis was initially detected. The results showed that MHE/DA (10 μg)-treated rats displayed neuronal apoptosis. However, we found that DA (10 μM) treatment did not induce evident apoptosis in primary cultured neurons (PCNs) but did produce TNF-α in primary cultured astrocytes (PCAs). Furthermore, co-cultures between PCAs and PCNs exposed to DA exhibited increased astrocytic TNF-α levels and neuronal apoptosis compared with co-cultures exposed to the vehicle, indicating the attribution of the neuronal apoptosis to astrocytic TNF-α. We also demonstrated that DA enhanced TNF-α production from astrocytes by activation of the TLR4/MyD88/NF-κB pathway, and secreted astrocytic TNF-α-potentiated neuronal apoptosis through inactivation of the PI3K/Akt/mTOR pathway. Overall, the findings from this study suggest that DA stimulates substantial production and secretion of astrocytic TNF-α, consequently and indirectly triggering progressive neurodegeneration, resulting in cognitive decline and memory loss in MHE.

Entities:  

Keywords:  Astrocytic TNF-α; Cognitive impairment; Dopamine (DA); Minimal hepatic encephalopathy (MHE); Neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 26433377     DOI: 10.1007/s12035-015-9445-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  52 in total

1.  ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro.

Authors:  Hongwei Qin; Etty N Benveniste
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

3.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

Review 4.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

5.  Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.

Authors:  Masaoki Kawasumi; Tomohiro Chiba; Marina Yamada; Makiko Miyamae-Kaneko; Masaaki Matsuoka; Jin Nakahara; Taisuke Tomita; Takeshi Iwatsubo; Shigeaki Kato; Sadakazu Aiso; Ikuo Nishimoto; Keisuke Kouyama
Journal:  Eur J Neurosci       Date:  2004-05       Impact factor: 3.386

Review 6.  Cytokines role in neurodegenerative events.

Authors:  Barbara Viviani; Stefano Bartesaghi; Emanuela Corsini; Corrado L Galli; Marina Marinovich
Journal:  Toxicol Lett       Date:  2004-04-01       Impact factor: 4.372

7.  Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.

Authors:  Ahmed A Moustafa; Mohammad M Herzallah; Mark A Gluck
Journal:  Neurodegener Dis       Date:  2012-11-01       Impact factor: 2.977

8.  Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication.

Authors:  S Fleminger; D L Oliver; S Lovestone; S Rabe-Hesketh; A Giora
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

9.  Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Authors:  Kamal S Saini; Sherene Loi; Evandro de Azambuja; Otto Metzger-Filho; Monika Lamba Saini; Michail Ignatiadis; Janet E Dancey; Martine J Piccart-Gebhart
Journal:  Cancer Treat Rev       Date:  2013-05-03       Impact factor: 12.111

10.  Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making.

Authors:  Elizabeth J Coulthard; Rafal Bogacz; Shazia Javed; Lucy K Mooney; Gillian Murphy; Sophie Keeley; Alan L Whone
Journal:  Brain       Date:  2012-10-31       Impact factor: 13.501

View more
  5 in total

Review 1.  The Role of Glia in Addiction: Dopamine as a Modulator of Glial Responses in Addiction.

Authors:  Ariadna Jiménez-González; Claudia Gómez-Acevedo; Abraham Ochoa-Aguilar; Anahí Chavarría
Journal:  Cell Mol Neurobiol       Date:  2021-05-31       Impact factor: 4.231

2.  DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy.

Authors:  Saidan Ding; Weishan Zhuge; Xuebao Wang; Jianjing Yang; Yuanshao Lin; Chengde Wang; Jiangnan Hu; Qichuan Zhuge
Journal:  Front Cell Neurosci       Date:  2017-09-06       Impact factor: 5.505

Review 3.  Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy.

Authors:  Weijia Han; Huanqian Zhang; Ying Han; Zhongping Duan
Journal:  Metab Brain Dis       Date:  2020-06-03       Impact factor: 3.584

Review 4.  Recent advances in hepatic encephalopathy.

Authors:  Victoria Liere; Gurkarminder Sandhu; Sharon DeMorrow
Journal:  F1000Res       Date:  2017-09-04

5.  Hydrogen sulphide ameliorates dopamine-induced astrocytic inflammation and neurodegeneration in minimal hepatic encephalopathy.

Authors:  Weishan Zhuge; Qichuan Zhuge; Weikan Wang; Xiaoai Lu; Ruimin You; Leping Liu; He Yu; Jian Wang; Xuebao Wang; Yiru Ye; Saidan Ding
Journal:  J Cell Mol Med       Date:  2020-10-28       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.